Citadel Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$218K Buy
+800
New +$208K ﹤0.01% 12107
2025
Q2
– Sell
-200
Closed -$34K – 13261
2025
Q1
$34K Buy
+200
New +$34.7K ﹤0.01% 12696
2023
Q4
– Sell
-200
Closed -$29.3K – 14559
2023
Q3
$29.3K Buy
+200
New +$30.5K ﹤0.01% 12286
2023
Q2
– Sell
-2,000
Closed -$310K – 14578
2023
Q1
$310K Buy
+2,000
New +$314K ﹤0.01% 9312
2022
Q1
– Sell
-2,300
Closed -$373K – 13877
2021
Q4
$373K Buy
+2,300
New +$372K ﹤0.01% 10412
2021
Q2
– Sell
-6,400
Closed -$1.03M – 13877
2021
Q1
$1.03M Buy
+6,400
New +$1.1M ﹤0.01% 8038
2020
Q1
– Sell
-2,300
Closed -$342K – 9749
2019
Q4
$342K Buy
2,300
+600
+35% +$82.4K ﹤0.01% 7389
2019
Q3
$210K Sell
1,700
-1,200
-41% -$160K ﹤0.01% 8091
2019
Q2
$408K Sell
2,900
-2,300
-44% -$317K ﹤0.01% 7116
2019
Q1
$784K Buy
+5,200
New +$748K ﹤0.01% 6021
2018
Q4
– Sell
-2,100
Closed -$333K – 9291
2018
Q3
$333K Sell
2,100
-1,600
-43% -$242K ﹤0.01% 7398
2018
Q2
$518K Sell
3,700
-1,900
-34% -$261K ﹤0.01% 6302
2018
Q1
$744K Buy
+5,600
New +$765K ﹤0.01% 5245
2017
Q3
– Sell
-6,000
Closed -$684K – 7658
2017
Q2
$684K Buy
+6,000
New +$645K ﹤0.01% 4664
2017
Q1
– Sell
-6,500
Closed -$591K – 7605
2016
Q4
$591K Sell
6,500
-2,400
-27% -$225K ﹤0.01% 4643
2016
Q3
$887K Buy
+8,900
New +$873K ﹤0.01% 3998

Other funds holding FBT

Citadel Advisors's FBT Position: Q3 2026 in Review

Citadel Advisors increased its First Trust NYSE Arca Biotechnology Index Fund (FBT) stake by 389% in Q3 2026, buying an estimated $5.42M and bringing the position to 26,224 shares worth $7.14M. The position accounts for ﹤0.01% of the portfolio, ranked #4220.

Citadel Advisors first reported a position in FBT in Q4 2014 and has held it in 42 quarters since. The position peaked at $9.4M in Q3 2015. 350 funds tracked by Wall St. Rank hold FBT as of Q3 2026.

  • Citadel Advisors held 26,224 shares of First Trust NYSE Arca Biotechnology Index Fund worth $7.14M as of Q3 2026.
  • Citadel Advisors bought 20,860 First Trust NYSE Arca Biotechnology Index Fund shares in Q3 2026, an estimated $5.42M.
  • First Trust NYSE Arca Biotechnology Index Fund made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #4220 holding.
  • Citadel Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2014 and has held it in 42 quarters since.
  • Citadel Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $9.4M in Q3 2015.
  • 350 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.